Facilitating the adoption of a new bladder cancer diagnostic test to support the management of urology waiting times post-COVID-19 lockdown

促进采用新的膀胱癌诊断测试，以支持 COVID-19 封锁后泌尿科等待时间的管理

• 批准号: 55608
• 金额: $ 9.04万
• 依托单位: ARQUER DIAGNOSTICS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=55608
• 关键词: Facilitating; adoption; new; bladder; cancer

This project will focus on the introduction of a novel technology to assist NHS in the stratification of urology patients (to ensure a quick diagnosis of patients at highest risk of having a bladder tumour). In the aftermath of COVID-19, patients presenting to NHS urology clinics will not be able to be prioritised with current tools. Arquer Diagnostics have a new Bladder Cancer Test (ADXBLADDER) which can be used to support the stratification of patients', thanks to its ability to rule out high risk tumours with a 98.7-99% certainty. Those patients with a negative test result have a very low chance of having a high risk tumour meaning they can safely delay having the invasive tests at the urology clinics, whilst those at high risk can be prioritised.Through this project a clinical team will be deployed by Arquer Diagnostics to identify those hospitals most in need of this stratification tool and to provide technical expertise for the installation of the test into NHS diagnostic laboratories. The team will also disseminate the relevant clinical and technical information to the NHS Urologists. These activities will provide NHS with a reliable stratification tool so that all the patients delayed during the COVID-19 crisis will be attended to with a strong clinical rationale, reducing the delay faced by those patients at highest risk, allowing these high risk tumours to be identified earlier and therefore improving their outcome.Additional funding will allow Arquer to design and conduct a survey of 50 urologists and 20 bladder cancer patients to understand the desire and willingness to use ADXBLADDER and to understand how differently urologists and patients view the technology. The results of this survey will allow Arquer to ensure that the evidence available for the test is presented in a way that demonstrates the greatest value of ADXBLADDER to both urologists and patients alike. This will ensure that when ADXBLADDER is assessed by NICE, the evidence supports this, which will facilitate the eventual adoption of the technology,

该项目将重点介绍一种新技术，以帮助国民健康保险制度对泌尿科患者进行分层(以确保对有最高风险患膀胱癌的患者进行快速诊断)。在新冠肺炎之后，到国民健康保险制度泌尿外科诊所就诊的患者将无法使用当前的工具优先处理。Arquer Diagnostics有一种新的膀胱癌测试(ADXBLADDER)，可以用来支持患者的分层，这要归功于它能够以98.7-99%的确定性排除高危肿瘤。那些检测结果为阴性的患者罹患高风险肿瘤的几率非常低，这意味着他们可以安全地推迟在泌尿科诊所进行侵入性测试，而那些高风险的患者可以被优先考虑。通过这个项目，Arquer Diagnostics将部署一个临床团队，以确定哪些医院最需要这种分层工具，并为将测试安装到NHS诊断实验室提供技术专业知识。该团队还将向NHS的泌尿科医生传播相关的临床和技术信息。这些活动将为英国国民健康保险制度提供可靠的分层工具，以便所有在新冠肺炎危机期间延误的患者将得到强有力的临床理由的照顾，减少那些高风险患者面临的延误，使这些高风险肿瘤能够更早被发现，从而改善他们的结果。额外资金将使Arquer能够设计和进行一项针对50名泌尿科医生和20名膀胱癌患者的调查，以了解使用ADXBLADDER的意愿和意愿，并了解泌尿科医生和患者对该技术的看法有何不同。这项调查的结果将使Arquer能够确保测试可用的证据以一种方式展示ADXBLADDER对泌尿科医生和患者的最大价值。这将确保当NICE评估ADXBLADDER时，证据支持这一点，这将促进该技术的最终采用，